CAR-T Cell Therapy: Who Qualifies and What It Costs

CAR-T is the closest thing oncology has to a bespoke drug: your own immune cells are removed, genetically rewritten in a laboratory to recognise your cancer, multiplied, and infused back. For some patients who had run out of options, it has produced remissions lasting years. It is also demanding, expensive, and available only for specific diseases — here is who it actually fits.

How the process works, step by step

1. Collection. T-cells are separated from your blood over a few hours, using a machine similar to a dialysis circuit.
2. Engineering. In a specialised laboratory a receptor — the chimeric antigen receptor — is inserted so the cells recognise a protein on your cancer, commonly CD19 or BCMA.
3. Expansion. The modified cells are multiplied into the millions. This step is why the wait is typically three to five weeks.
4. Bridging therapy. While you wait, chemotherapy may be given to keep the disease under control.
5. Lymphodepletion. A short course of chemotherapy clears space in the immune system a few days before infusion.
6. Infusion and monitoring. The cells go back in a single bag; the critical observation period is the next two to four weeks.

Which diseases and which patients

Approved CAR-T products target blood cancers: aggressive B-cell lymphomas, follicular and mantle cell lymphoma, B-cell acute lymphoblastic leukaemia in younger patients, and multiple myeloma. Solid tumours remain an area of active research rather than routine treatment — be cautious of any clinic offering CAR-T for breast, lung or colon cancer outside a registered clinical trial.

• Usually offered after two or more previous lines of treatment have failed, though it is moving earlier in some lymphomas.
• Requires adequate heart, lung, liver and kidney function to tolerate the reaction.
• Requires no uncontrolled infection and no active central nervous system complication at the time of infusion.
• Requires a caregiver and the ability to stay within roughly an hour of the treating centre for several weeks.

The side effects that need a hospital

Two reactions define CAR-T. Cytokine release syndrome is the immune system switching on hard: fever, low blood pressure, breathlessness, usually within the first week. Neurotoxicity can cause confusion, difficulty finding words, tremor or seizures. Both are treatable — tocilizumab and steroids are given by protocol — but both need a unit that has seen them before, with intensive care next door.

Cost and access

In the United States the product alone is listed at roughly $400,000 to $550,000, and the total episode of care — collection, bridging, admission, complications — frequently passes $1 million. The cell product is manufactured by a small number of licensed facilities worldwide, so the price of the drug itself does not vary much between countries; what varies is the hospital cost around it.

Because of that structure, the honest advice for most patients is to check three things before travelling anywhere: whether an approved product exists for your exact diagnosis, whether a licensed transplant-and-cell-therapy unit will accept your case, and whether a clinical trial at home would provide the same therapy without the price. We will tell you when the answer is no.

Frequently asked questions

How long does the whole CAR-T process take?

Plan on two to three months from the first assessment: a few days for collection, three to five weeks of manufacturing, two to three weeks in hospital around the infusion, and close follow-up afterwards.

Is CAR-T a cure?

For a subset of patients with aggressive lymphoma or leukaemia, remissions have now lasted many years and look durable. For others the disease returns, sometimes because the cancer stops displaying the target protein. It is a powerful option, not a guarantee.

Can I have CAR-T if I already had a stem cell transplant?

Often yes — many approved indications are specifically for patients who relapsed after a transplant. The team will check your blood counts, organ function and any graft-versus-host disease before deciding.